All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Halpryza
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Halpryza (rituximab injection) is Innovent’s fourth monoclonal antibody drug approved by the NMPA following TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab injection).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Collaboration October 07, 2020
Details:
Innovent Biologics announce the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with global expansion collaboration agreement between the company and Eli Lilly for TYVYT (sintilimab injection).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niraparib
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities
Deal Size: $766.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 22, 2020
Details:
The Company plans to use the net proceeds for R&D efforts in respect to, and commercialization for, its core products which includes lead drug Zejula, fund its ongoing and planned clinical trials and preparation for registration filings of other drug candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niraparib
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
ZEJULA was recommended as a monotherapy first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer in the Ovarian Cancer PARP Inhibitor Clinical Guidelines published by Gynecological Oncology, Chinese Medical Association.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Zercepac
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2020
Details:
Trastuzumab biosimilar (HLX02, EU brand name: Zercepac®), developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neratinib Maleate
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
Details:
CANbridge has received marketing approval from the Taiwan Food and Drug Administration for NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: DCC-2618
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
China’s NMPA has granted priority review status to the New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Almonertinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: EQRx
Deal Size: Undisclosed Upfront Cash: $100.0 million
Deal Type: Licensing Agreement July 23, 2020
Details:
Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: ATG-010
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Fidelity Management & Research Company
Deal Size: $97.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing July 21, 2020
Details:
Proceeds from the Series C financing will be primarily used to fund the continuing clinical development of Antengene's robust pipeline of hematology and oncology therapies, expanding in-house R&D capabilities and strengthening the commercial infrastructures in APAC markets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Denosumab
Therapeutic Area: Oncology Product Name: Xgeva
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $421.0 million Upfront Cash: Undisclosed
Deal Type: Investment July 12, 2020
Details:
This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
